Clinical Study
Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade
Table 1
Patient characteristics (
).
| Mean age, years (range) | 70.9 | (52–92) | Mean PSA at the diagnosis, ng/mL (range) | 760 | (17.2–5740) | Clinical stage, (%) | | | T2 | 1 (5) | | T3 | 11 (55) | | T4 | 8 (40) | | Gleason score, (%) | | | ≤6 | 1 (5) | | 7 | 3 (15) | | 8 | 4 (20) | | 9 | 11 (55) | | 10 | 1 (5) | | Response to first-line CAB therapy, (%) | | | Response | 17 (85) | | PR | 3 (15) | |
|
|
CAB: combined androgen blockade; PR: partial remission.
|